Discussing the Cures Act and New FDA Draft Guidance on Communication

In a post on the the IVI-sponsored Health Affairs blog series, Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payers and formulary committees about the real-world impacts of their products. Read the [...]

2017-07-14T07:24:21-04:00February 2nd, 2017|Viewpoints|

Cost-Effectiveness 2.0: Poised for a Second Act?

Peter Neumann and co-author Gillian Sanders offer a new perspective on cost-effectiveness analysis in a new article published in the New England Journal of Medicine. Neumann and Sanders provide an overview of recent work and argue that cost-effectiveness analysis should be an essential component of healthcare decision-making. Read the full article here.

2017-07-14T07:24:34-04:00January 19th, 2017|Viewpoints|

Germany’s Drug Price Model: Would it Work in the U.S.?

In a recent post on the IVI-sponsored Health Affairs blog series, Karl Lauterbach, John McDonough, and Elizabeth Seely suggest that Germany's AMNOG (the Act to Reorganize Pharmaceuticals Market in the Statutory Health Insurance System or Arzneimittelmarktneuordnungsgesetz) model should be applied to U.S. drug pricing policy. Read the full article here. About the Health Affairs/IVI Featured Blog Series: [...]

2017-07-14T05:26:27-04:00December 29th, 2016|Viewpoints|

The Demise of the Medicare Part B Demo

In a recent post on the IVI-sponsored Health Affairs blog series, Rachel Dolan looks at resistance to specific policies that attempt to move towards value-based reimbursement. Despite widespread bipartisan agreement that Medicare Part B should be paying for value, roadblocks are still formidable. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs [...]

2017-07-14T07:24:56-04:00December 27th, 2016|Viewpoints|

21st Century Cures Legislation a Bad Deal for Patients

In a recent post on the IVI-sponsored Health Affairs blog series, Ameet Sarpatwari and Michael Sinha discuss why the 21st Century Cures legislation increases risk of patient harm. Among the issues they highlight are uncertainty around funding -- especially for prevention, research, and regulatory science -- and the loosening of evidence standards for FDA approvals. [...]

2017-07-14T07:25:30-04:00November 30th, 2016|Viewpoints|

Divorcing Reimbursement From Real-World Prices

In a recent post on the IVI-sponsored Health Affairs blog series, David Tawes and Marta Wosinka examine consequences of the disconnection between market prices and reimbursement, specifically in that Medicare still uses 2003 average wholesale prices (AWPs) for some drugs. Tawes and Wosinka point out that, in the case of drugs where the actual costs [...]

2017-07-14T07:25:46-04:00November 21st, 2016|Viewpoints|

Regulatory, Legal Uncertainties are Barriers to Value-Based Agreements

Alison Sexton Ward, Mark Linthicum, Michelle Drozd, Alison Silverstein, and Joe Vandigo identify key legal and regulatory barriers in the creation of value-based contracts for drugs in their recent addition to the IVI-sponsored Health Affairs blog series. Based on two-part, in-depth interviews with a group of five stakeholders regarding their experience with value-based agreements, the authors identify [...]

2017-07-14T07:26:10-04:00November 4th, 2016|Viewpoints|

Responding to President Obama on the Affordable Care Act

Amitabh Chandra and co-author Jonathan Skinner respond to President Obama's JAMA letter describing the success of the Affordable Care Act (ACA), concluding that, while the landmark legislation suffers from a number of fundamental problems, it is also "far more moderate, innovative -- and difficult to replace -- than its critics claim." Read the full article [...]

2017-07-14T07:28:27-04:00August 2nd, 2016|Viewpoints|

Reforming Medicare’s Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism

Expanding services covered by a “bundled payment” can also expand variation in the costs of treating patients under the bundle. In this article, Charu Gupta et al.explore this topic further using the Medicare dialysis program as an example. Source: Health Services Research

2020-03-19T15:49:54-04:00July 14th, 2014|Publications|
Go to Top